Dare Bioscience, Inc. Common Stock
DAREDare Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products for women’s reproductive health and sexual wellness. The company's pipeline includes treatments for fertility, contraception, and other gynecological conditions, aiming to address unmet medical needs in women's health.
Company News
Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.
Daré Bioscience announced a webinar on August 6, 2025, introducing DARE to PLAY™, a novel sildenafil cream designed to improve female sexual arousal, targeting prescription availability in Q4 2025.
Daré Bioscience announced positive findings from a Phase 2b study of its investigational topical cream Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD). The study showed consistent results from patient-reported outcome measures, regardless of recall period, supporting the use of longer recall intervals which are ...
Dare Bioscience, a biopharmaceutical company focused on women's health, has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock achieved the necessary closing bid price of $1.00 or more per share over 10 consecutive trading sessions.
Daré Bioscience, a biopharmaceutical company focused on women's health, announced that it has regained compliance with the Nasdaq minimum bid price requirement. The company is advancing its pipeline of potential first-in-category product candidates, including Ovaprene, a hormone-free monthly contraceptive, and Sildenafil Cream for female sexual ...
